Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a confirmed diagnosis of relapsing remitting MS per the 2010 McDonald criteria.~* Must have a known tetanus immunization history with most recent tetanus vaccination given 2 to 15 years prior to Screening and an anti-tetanus serum immunoglobulin titer at Screening that is less than or equal to one-half the upper limit of detection for the assay.~* Must have been on a stable approved dose of Tecfidera (240 mg twice daily \[BID\]) \[Group 1\] for ≥6 months or on a stable approved dose of a non-pegylated IFN (e.g., Avonex, Betaseron, Rebif, Extavia) \[Group 2\] for ≥3 months prior to Day 1.~Key Exclusion Criteria:~* Clinical relapse requiring treatment within 30 days prior to Day 1.~* Pneumococcal vaccination within 5 years prior to Screening.~* Previous exposure to meningococcal vaccines.~* Known hypersensitivity to Td, PPSV23, or MCV4 or their components.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Non-Pegylated IFN Treated Plus Vaccinations (Type: ACTIVE_COMPARATOR): Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL
- Tecfidera Treated Plus Vaccinations (Type: EXPERIMENTAL): Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).